论文部分内容阅读
目的 观察肿瘤坏死因子α(TNFα)在不同类型非小细胞肺癌患者的血清水平 ,并探讨TNFα与非小细胞肺癌患者的临床特征和临床疗效的关系。方法 以 40例非小细胞肺癌患者为研究组 ,2 0例正常健康者为对照组 ,用双抗体夹心ELISA法测定其血清水平。结果 非小细胞肺癌患者血清TNFα水平显著高于正常对照组 (P <0 .0 1 ) ,不同类型非小细胞肺癌间比较差异无显著性 ,但有远处转移者血清TNFα水平显著高于无远处转移者 (P <0 .0 5) ,化疗有效组血清TNFα水平较化疗前明显下降 (P <0 .0 5)。结论 非小细胞肺癌患者血清TNFα水平升高 ,且与病情的严重程度及化疗的临床疗效有关。本研究提示检测血清TNFα水平可用于判断非小细胞肺癌的病情和疗效评估
Objective To observe the serum levels of tumor necrosis factor α (TNFα) in patients with different types of non-small cell lung cancer and to explore the relationship between the clinical features and clinical efficacy of TNFα in patients with non-small cell lung cancer. Methods Forty patients with non-small cell lung cancer were selected as research group and twenty normal controls as control group. Serum levels were measured by double antibody sandwich ELISA. Results The level of serum TNFα in patients with NSCLC was significantly higher than that in the normal control group (P <0.01). There was no significant difference between the different types of NSCLC, but the level of TNFα in patients with distant metastasis was significantly higher than that in the non-small cell lung cancer In distant metastasis (P <0.05), the level of serum TNFα in the chemotherapy-effective group was significantly lower than that before chemotherapy (P <0.05). Conclusion Serum TNFα levels are elevated in patients with non-small cell lung cancer and are related to the severity of the disease and the clinical efficacy of chemotherapy. This study suggests that the detection of serum TNFα level can be used to determine the condition and efficacy of non-small cell lung cancer